Sarepta Gets JPMorgan Upgrade, but Wedbush Sees Risk

Forward-Looking Analysis

Analysts project Sarepta’s 2026Q2 revenue to reach $785.4 million, reflecting a 7.5% year-over-year increase driven primarily by sustained demand for Amvuttra (vutrisiran) in transthyretin amyloidosis. Net income is forecasted at $362.1 million, up from the previous year’s $330.96 million, indicating improved operating leverage and cost management efficiency. Earnings per share (EPS) are expected to hit $3.42, surpassing the consensus estimate of $3.38, suggesting robust profitability metrics. Major investment banks, including Goldman Sachs and Morgan Stanley, have maintained their 'Buy' ratings with price targets raised to $185 and $190 respectively, citing accelerating commercial execution. JPMorgan upgraded the stock to 'Overweight' with a $195 target, highlighting the expanding addressable market for vutrisiran. Conversely, Wedbush maintained a 'Neutral' stance, warning of potential reimbursement headwinds in Q3, though they acknowledged the strong Q2 trajectory. Consensus estimates from Bloomberg and Refinitiv align with the $3.42 EPS projection, with a tight standard deviation indicating high analyst confidence. No significant downgrades have been issued in the past month, reinforcing a predominantly positive sentiment. The focus remains on the uptake of Elivaptan in myotonic dystrophy and potential new indications for the gene therapy portfolio, which could provide additional upside surprises beyond current conservative models.

Historical Performance Review

Sarepta delivered a robust performance in 2026Q1, recording revenue of $730.80 million, which demonstrated strong commercial traction. Net income surged to $330.96 million, reflecting effective cost controls and high-margin product sales. EPS reached $3.15, exceeding market expectations and validating the company’s strategic focus on Amvuttra. Gross profit stood at $622.03 million, yielding a healthy gross margin that underscores pricing power and operational efficiency. These figures set a high baseline for Q2, with analysts anticipating continued growth momentum.

Additional News

Sarepta recently announced the initiation of a Phase 3 clinical trial for Elivaptan in patients with myotonic dystrophy type 1, marking a significant expansion into new therapeutic areas. CEO David Cohen highlighted the company’s commitment to innovation during the recent JP Morgan Healthcare Conference, emphasizing the pipeline’s potential to address unmet needs in neuromuscular disorders. The company also secured a strategic partnership with a major European distributor to enhance market access for Amvuttra across key EU territories. Additionally, Sarepta announced a $500 million share repurchase program, signaling confidence in its cash flow generation. These developments underscore the company’s diversified growth strategy beyond its core amyloidosis franchise.

Summary & Outlook

Sarepta exhibits strong financial health, evidenced by rising revenue, net income, and EPS trends. Growth catalysts include the expanding adoption of Amvuttra and promising Phase 3 data for Elivaptan. While reimbursement risks exist, the company’s robust cash flow and strategic partnerships mitigate downside concerns. The overall outlook is bullish, with consistent analyst upgrades and positive clinical updates supporting future prospects. Investors should anticipate continued upward momentum in the near term, driven by commercial execution and pipeline advancements.